recombinant camelid-derived single-domain antibody radioimmunotherapeutics (Precirix)

N/A

Report date: 2025/03/20 09:43:06

Base Information

Drug Namerecombinant camelid-derived single-domain antibody radioimmunotherapeutics (Precirix)

Drug Alias NameCAM-alphaCAM-betarecombinant camelid-derived single-domain antibody radioimmunotherapeutics (Camel-IDS)

ClassificationBiologics > Protein drugs > Recombinant proteinRadiation-emitting products > Radioactive therapeutic agentBiologics > Protein drugs > Immunoglobulin > Antibody

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesPrecirix

China Registration ClassN/A

Develop Information

Active CompaniesPrecirix

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A